The content on this site is intended for healthcare professionals only
Prof Finn talks to ecancer at at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about the results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for firstline treatment of ER+/HER2- advanced breast cancer.
The new compound has the potential to be a standard of care in this setting, if a phase 3 study is successful, and also has promise in the adjuvant setting.
Filming Supported by Amgen
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
ESMO 2024: Highlights and analysis
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
ASCO 2023: Breast cancer research highlights
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
